Consensus estimates for Summit Therapeutics point to a Q3 2026 loss of $0.28 per share on minimal revenue of approximately $0.05 million, while the current stock price of $15.55 remains significantly below the average analyst target of $28.61.
Investors are primarily focused on management's commentary regarding the impending November 14, 2026, PDUFA date for ivonescimab in non-small cell lung cancer.
This reporting period follows a transformative $2 billion strategic investment from AstraZeneca in early October, which has dramatically strengthened the company's balance sheet. Analysts will be scrutinizing updated cash runway projections and the clinical expansion plans for the ivonescimab pipeline following the recent partnership milestone.